Red Rock Resorts earnings beat by $0.54, revenue topped estimates
Investing.com -- Pfizer Inc. (NYSE:PFE) reported positive topline Phase 3 results for its hemophilia treatment HYMPAVZI in patients with hemophilia A or B with inhibitors.
The pharmaceutical company said HYMPAVZI demonstrated superiority in reducing bleeding outcomes compared to other treatments.
The drug showed a 93% reduction in annualized bleeding rate in trial participants.
According to Pfizer, HYMPAVZI was generally well-tolerated during the clinical trials, with no deaths or thromboembolic events reported among participants.
The company plans to initiate regulatory filings for HYMPAVZI based on these positive results, seeking approval for the treatment’s use in hemophilia patients with inhibitors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.